The collapse of Theranos and the subsequent travails of its founder, Elizabeth Holmes, may well have cooled somewhat the formerly white-hot search of venture capitalists for the next great high-tech unicorn.
After the verdict, Bijan Salehizadeh, holder of an MD from the Columbia University College of Physicians and Surgeons (1999), and an investor at Highland Capital Partners, reminisced for The New York Times about his reluctance to invest in Theranos in its early years, and how he came to question that judgment while listening to the venture capitalists hanging out at the Rosewood . . .
Continue Reading
Not a subscriber yet? Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.